Leukemia Research
Volume 28, Issue 10 , Pages 1023-1031 , October 2004

Growth and apoptosis of human natural killer cell neoplasms: role of interleukin-2/15 signaling

  • Satoshi Yamasaki

      Affiliations

    • Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan
    • Corresponding Author InformationCorresponding author. Tel.: +81-92-642-5947; fax: +81-92-642-5951.
    • ,
  • Motoi Maeda

      Affiliations

    • Terry Fox Laboratory, British Columbia Cancer Agency, 601 West 10th Avenue, Vancouver, BC, Canada V5Z 1L3
    • ,
  • Koichi Ohshima

      Affiliations

    • Department of Pathology, School of Medicine, Fukuoka University, 7-45-1 Nanakuma, Jounan-ku, Fukuoka 814-0180, Japan
    • ,
  • Masahiro Kikuchi

      Affiliations

    • Department of Pathology, School of Medicine, Fukuoka University, 7-45-1 Nanakuma, Jounan-ku, Fukuoka 814-0180, Japan
    • ,
  • Teruhisa Otsuka

      Affiliations

    • Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan
    • ,
  • Mine Harada

      Affiliations

    • Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan

Received 22 December 2003 ,Accepted 23 February 2004.

References 

  1. Imamura N, Kusunoki Y, Kawa-Ha K, Yumura K, Hara J, Oda K, et al.  Aggressive natural killer cell leukaemia/lymphoma: report of four cases and review of the literature. Br. J. Haematol. 1990;75:49–59
  2. Chan JK, Sin VC, Wong KF, Ng CS, Tsang WY, Chan CH, et al.  Nonnasal lymphoma expressing the natural killer cell marker CD56: a clinicopathologic study of 49 cases of an uncommon aggressive neoplasm. Blood. 1997;89:4501–4513
  3. Koita H, Suzumiya J, Ohshima K, Takeshita M, Kimura N, Kikuchi M, et al.  Lymphoblastic lymphoma expressing natural killer cell phenotype with involvement of the mediastinum and nasal cavity. Am. J. Surg. Pathol. 1997;21:242–248
  4. Kwong YL, Chan AC, Liang R, Chiang AK, Chim CS, Chan TK, et al.  CD56 + NK lymphomas: clinicopathological features and prognosis. Br. J. Haematol. 1997;97:821–829
  5. Li CC, Tien HF, Tang JL, Yao M, Chen YC, Su IJ, et al.  Treatment outcome and pattern of failure in 77 patients with sinonasal natural killer/T-cell or T-cell lymphoma. Cancer. 2004;100:366–375
  6. Jaffe ES, Ralfkiaer E. Mature T-cell, NK-cell neoplasms. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. Tumors of Haematopoietic and Lymphoid Tissue. Lyon (France): IARC Press; 2001. p. 214–5.
  7. Chiang AKS, Srivastava G, Lau PWF, Ho FCS. Differences in T-cell-receptor gene rearrangement and transcription in nasal lymphomas of natural killer and T-cell types: implications on cellular origin. Hum. Pathol. 1996;27:701–707
  8. Liang R, Todd D, Chan TK, Chiu E, Lie A, Kwong YL, et al.  Treatment outcome and prognostic factors for primary nasal lymphoma. J. Clin. Oncol. 1995;13:666–670
  9. Cheung MM, Chan JK, Lau WH, Foo W, Chan PT, Ng CS, et al.  Primary non-Hodgkin’s lymphoma of the nose and nasopharynx: clinical features, tumor immunophenotype, and treatment outcome in 113 patients. J. Clin. Oncol. 1998;16:70–77
  10. Bower CP, Standen GR, Pawade J, Knechtli CJ, Kennedy CT. Cutaneous presentation of steroid responsive blastoid natural killer cell lymphoma. Br. J. Dermatol. 2000;142:1017–1020
  11. Drenou B, Lamy T, Amiot L, Fardel O, Caulet-Maugendre S, Sasportes M, et al.  CD3−CD56+ non-Hodgkin’s lymphomas with an aggressive behavior related to multidrug resistance. Blood. 1997;89:2966–2974
  12. Takenaka K, Shinagawa K, Maeda Y, Makita M, Kozuka T, Ashiba A, et al.  High-dose chemotherapy with hematopoietic stem cell transplantation is effective for nasal and nasal-type CD56+ natural killer cell lymphomas. Leuk. Lymphoma. 2001;42:1297–1303
  13. Burton JD, Bamford RN, Peters C, Grant AJ, Kurys G, Goldman CK, et al.  A lymphokine, provisionally designated interleukin T and produced by a human adult T-cell leukemia line, stimulates T-cell proliferation and the induction of lymphokine-activated killer cells. Proc. Natl. Acad. Sci. U.S.A. 1994;91:4935–4939
  14. Carson WE, Giri JG, Lindemann MJ, Linett ML, Ahdieh M, Paxton R, et al.  Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. J. Exp. Med. 1994;180:1395–1403
  15. Grabstein KH, Eisenman J, Shanebeck K, Rauch C, Srinivasan S, Fung V, et al.  Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor. Science. 1994;264:965–968
  16. Giri JG, Ahdieh M, Eisenman J, Shanebeck K, Grabstein K, Kumaki S, et al.  Utilization of the beta and gamma chains of the IL-2 receptor by the novel cytokine IL-15. J. Eur. Mol. Biol. Org. 1994;13:2822–2830
  17. Giri JG, Kumaki S, Ahdieh M, Friend DJ, Loomis A, Shanebeck K, et al.  Identification and cloning of a novel IL-15 binding protein that is structurally related to the alpha chain of the IL-2 receptor. J. Eur. Mol. Biol. Org. 1995;14:3654–3663
  18. Carson WE, Fehniger TA, Haldar S, Eckhert K, Lindemann MJ, Lai CF, et al.  A potential role for interleukin-15 in the regulation of human natural killer cell survival. J. Clin. Invest. 1997;99:937–943
  19. Lodolce JP, Boone DL, Chai S, Swain RE, Dassopoulos T, Trettin S, et al.  IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation. Immunity. 1998;9:669–676
  20. Fehniger TA, Suzuki K, Ponnappan A, VanDeusen JB, Cooper MA, Florea SM, et al.  Fatal leukemia in interleukin 15 transgenic mice follows early expansions in natural killer and memory phenotype CD8+ T cells. J. Exp. Med. 2001;193:219–231
  21. Waldmann TA. The IL-2/IL-15 receptor systems: targets for immunotherapy. J. Clin. Immunol. 2002;22:51–56
  22. Bamford RN, Battiata AP, Burton JD, Sharma H, Waldmann TA. Interleukin (IL) 15/IL-T production by the adult T-cell leukemia cell line HuT-102 is associated with a human T-cell lymphotrophic virus type I region/IL-15 fusion message that lacks many upstream AUGs that normally attenuates IL-15 mRNA translation. Proc. Natl. Acad. Sci. U.S.A. 1996;93:2897–2902
  23. Gong JH, Maki G, Klingemann HG. Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia. 1994;8:652–658
  24. Yagita M, Huang CL, Umehara H, Matsuo Y, Tabata R, Miyake M, et al.  A novel natural killer cell line (KHYG-1) from a patient with aggressive natural killer cell leukemia carrying a p53 point mutation. Leukemia. 2000;14:922–930
  25. Nagata H, Konno A, Kimura N, Zhang Y, Kimura M, Demachi A, et al.  Characterization of novel natural killer (NK)-cell and γδ T-cell lines established from primary lesions of nasal T/NK-cell lymphomas associated with the Epstein–Barr virus. Blood. 2001;97:708–713
  26. Kagami Y, Nakamura S, Suzuki R, Iida S, Yatabe Y, Okada Y, et al.  Establishment of an IL-2-stimulated cell line derived from ‘nasal-type’ NK/T-cell lymphoma of CD2+, sCD3−, CD3ε+, CD56+ phenotype and associated with the Epstein–Barr virus. Br. J. Haematol. 1998;103:669–677
  27. Matsuo Y, Drexler HG, Takeuchi M, Tanaka M, Orita K. Establishment of the T-cell large granular lymphocyte leukemia cell line MOTN-1 carrying natural killer-cell antigens. Leuk. Res. 2002;26:873–879
  28. Ohshima K, Suzumiya J, Sugihara M, Kanda M, Shimazaki K, Kawasaki C, et al.  Clinical, immunohistochemical and phenotypic features of aggressive nodal cytotoxic lymphomas, including alpha/beta, gamma/delta T-cell and natural killer cell types. Virchows Arch. 1999;435:92–100
  29. Bulfone-Paus S, Durkop H, Paus R, Krause H, Pohl T, Onu A. Differential regulation of human T lymphoblast function by IL-2 and IL-15. Cytokine. 1997;9:507–513
  30. Raff T, van der G, Endemann D, Wiederholt T, Paul M. Design and testing of β-actin primers for RT-PCR that do not co-amplify processed pseudogenes. Biotechnique. 1997;23:456–460
  31. Ruckert R, Asadullah K, Seifert M, Budagian VM, Arnold R, Trombotto C, et al.  Inhibition of keratinocyte apoptosis by IL-15: a new parameter in the pathogenesis of psoriasis. J. Immunol. 2000;165:2240–2250
  32. Kurowska M, Rudnicka W, Kontny E, Janicka I, Chorazy M, Kowalczewski J, et al.  Fibroblast-like synoviocytes from rheumatoid arthritis patients express functional IL-15 receptor complex: endogenous IL-15 in autocrine fashion enhances cell proliferation and expression of Bcl-x(L) and Bcl-2. J. Immunol. 2002;169:1760–1767
  33. Neely GG, Robbins SM, Amankwah EK, Epelman S, Wong H, Spurrell JC, et al.  Lipopolysaccharide-stimulated or granulocyte-macrophage colony-stimulating factor-stimulated monocytes rapidly express biologically active IL-15 on their cell surface independent of new protein synthesis. J. Immunol. 2001;167:5011–5017
  34. Mrozek E, Anderson P, Caligiuri MA. Role of interleukin-15 in the development of human CD56+ natural killer cells from CD34+ hematopoietic progenitor cells. Blood. 1996;184:325–336
  35. Leclercq G, Debacker V, de Smedt M, Plum J. Differential effects of interleukin-15 and interleukin-2 on differentiation of bipotential T/natural killer progenitor cells. J. Exp. Med. 1996;184:325–336
  36. Murray AM, Simm B, Beagley KW. Cytokine gene expression in murine fetal intestine: potential for extrathymic T cell development. Cytokine. 1998;10:337–345
  37. Koka R, Burkett PR, Chien M, Chai S, Chan F, Lodolce JP, et al.  Interleukin (IL)-15R{alpha}-deficient natural killer cells survive in normal but not IL-15R{alpha}-deficient mice. J. Exp. Med. 2003;197:977–984
  38. Dubois S, Mariner J, Waldmann TA, Tagaya Y. IL-15R-alpha recycles and presents IL-15 in trans to neighboring cells. Immunity. 2002;17:537–547
  39. Minagawa M, Watanabe H, Miyaji C, Tomiyama K, Shimura H, Ito A, et al.  Enforced expression of Bcl-2 restores the number of NK cells, but does not rescue the impaired development of NKT cells or intraepithelial lymphocytes, in IL-2/IL-15 receptor beta-chain-deficient mice. J. Immunol. 2002;169:4153–4160
  40. Masuda A, Matsuguchi T, Yamaki K, Hayakawa T, Yoshikai Y. Interleukin-15 prevents mouse mast cell apoptosis through STAT6-mediated Bcl-xL expression. J. Biol. Chem. 2001;276:26107–26113

PII: S0145-2126(04)00057-8

doi: 10.1016/j.leukres.2004.02.006

Leukemia Research
Volume 28, Issue 10 , Pages 1023-1031 , October 2004

Article Tools

* Image Usage & Resolution